drug · small molecule
tucidinostat
Phase 2updated 3mo agoby HUYA Bioscience International LLC🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for non-small cell lung carcinoma and neoplasm and 37 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying tucidinostat
- phase2A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
- phase3Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
- phase3A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
- phase3Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 53m ago
Found something off?
comments(0)
5-min edit window · permanent after that